Intermediate malignant teratoma

Summary

Intermediate malignant teratoma (MONDO:0004140) is a disease. A subtype of malignant teratoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intermediate malignant teratoma
Mondo ID	MONDO:0004140
DOID	DOID:7202
NCIT	C4288
UMLS	C0334522
MedGen	83161
GARD	0023842
Is cancer (heuristic)	no

Also known as: Intermediate immature teratoma · malignant teratoma, intermediate · malignant teratoma, intermediate (morphologic abnormality)

Disease family

This is a subtype of malignant teratoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › nongerminomatous germ cell tumor › teratoma › malignant teratoma › intermediate malignant teratoma

Related subtypes (6): pineal region immature teratoma, immature gastric teratoma, immature ovarian teratoma, malignant teratoma of testis, malignant teratoma of mediastinum, immature extragonadal teratoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.